Regulatory T cells converted from Th1 cells in tumors suppress cancer immunity via CD39
Journal of Experimental Medicine · 07.04.2025 · 222 (4)
DOI: 10.1084/jem.20240445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 05.02.2025. Verfasst von Sang-Nee Tan und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Westlake University , Hangzhou, China. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Th1 Cells, Neoplasms, Apyrase. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: China Postdoctoral Science Foundation, Center for Life Sciences at Tsinghua-Peking Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
Regulatory T (Treg) cells are known to impede antitumor immunity, yet the regulatory mechanisms and functional roles of these cells remain poorly understood. In this study, through the characterization of multiple cancer models, we identified a substantial presence of peripherally induced Treg cells in the tumor microenvironment (TME). Depletion of these cells triggered antitumor responses and provided potent therapeutic effects by increasing functional CD8+ T cells. Fate-mapping and transfer experiments revealed that IFN-γ–expressing T helper (Th) 1 cells differentiated into Treg cells in response to TGF-β signaling in tumors. Pseudotime trajectory analysis further revealed the terminal differentiation of Th1-like Treg cells from Th1 cells in the TME. Tumor-resident Treg cells highly expressed T-bet, which was essential for their functions in the TME. Additionally, CD39 was highly expressed by T-bet+ Treg cells in both mouse and human tumors, and was necessary for Treg cell-mediated suppression of CD8+ T cell responses. Our study elucidated the developmental pathway of intratumoral Treg cells and highlighted novel strategies for targeting them in cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Medicine, Westlake University , Hangzhou, China.
- Institute for Immunology and School of Medicine, Tsinghua University , Beijing, China.
- Shanghai Immune Therapy Institute, Shanghai Jiao Tong University School of Medicine-affiliated Renji Hospital , Shanghai, China.
- Department of Hepatobiliary Surgery, China-Japan Friendship Hospital, Beijing, China.
- School of Pharmaceutical Sciences, Shanghai Jiao Tong University , Shanghai, China.
ORCID-Profile: Sang-Nee Tan, Jing Hao, Jing Ge, Yazheng Yang, Liguo Liu, Jia Huang, Meng Lin, Xiaohong Zhao, Genyu Wang, Zhiying Yang, Ling Ni, Chen Dong
Förderung
- China Postdoctoral Science Foundation
- Center for Life Sciences at Tsinghua-Peking Universities
- National Natural Science Foundation of China
- Innovative research team of high-level local universities in Shanghai
- Zhejiang Provincial Natural Science Foundation of China
- National Key Research and Development Program of China
- Tsinghua University-Xiamen Chang Gung Hospital Joint Research Center for Anaphylactic Disease
Zitieren
APA
Tan, S. N., Hao, J., Ge, J., Yang, Y., Liu, L., Huang, J., Lin, M., Zhao, X., Wang, G., Yang, Z., Ni, L., & Dong, C. (2025). Regulatory T cells converted from Th1 cells in tumors suppress cancer immunity via CD39. Journal of Experimental Medicine, 222(4). https://doi.org/10.1084/jem.20240445
Vancouver
Tan SN, Hao J, Ge J, Yang Y, Liu L, Huang J, et al. Regulatory T cells converted from Th1 cells in tumors suppress cancer immunity via CD39. Journal of Experimental Medicine. 2025;222(4). doi:10.1084/jem.20240445
BibTeX
@article{Tan2025,
author = {Tan, Sang-Nee and Hao, Jing and Ge, Jing and Yang, Yazheng and Liu, Liguo and Huang, Jia and Lin, Meng and Zhao, Xiaohong and Wang, Genyu and Yang, Zhiying and Ni, Ling and Dong, Chen},
title = {Regulatory T cells converted from Th1 cells in tumors suppress cancer immunity via CD39},
journal = {Journal of Experimental Medicine},
year = {2025},
volume = {222},
number = {4},
doi = {10.1084/jem.20240445}
}
EUVIMED